CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Combination Treatment of Sorafenib and Resminostat, a new HDAC Inhibitor, in Patients with Sorafenib-resistant Hepatocellular Carcinoma (HCC) – Results of the Dose-Escalation Phase
DOI 10.1055/s-0031-1295962
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Bitzer, M Horger, TM Ganten, J Siveke, MA Woerns, M Dollinger, G Gerken, ME Scheulen, H Wege, A Mais, R Jankowsky, B Hauns, B Hentsch, UM Lauer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Resminostat (4SC–201), an orally taken pan-HDAC inhibitor, is currently under investigation in various oncological indications. The Phase I/II SHELTER study aims to evaluate safety, tolerability and efficacy in HCC patients (pts) exhibiting progressive disease under sorafenib (S) first-line therapy. Methods: Pts with advanced HCC (BCLC B, C) are included in a multi-center, open-label, two-arm parallel group tr…
Zitieren
Zitierempfehlung
M Bitzer, M Horger, TM Ganten, J Siveke, MA Woerns, M Dollinger, G Gerken, ME Scheulen, H Wege, A Mais, R Jankowsky, B Hauns, B Hentsch, UM Lauer (2012) Combination Treatment of Sorafenib and Resminostat, a new HDAC Inhibitor, in Patients with Sorafenib-resistant Hepatocellular Carcinoma (HCC) – Results of the Dose-Escalation Phase. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0031-1295962
Mit CareLit weiterarbeiten